4 active trials 2 recruiting 3 Phase 3 5 disease areas
| Phase 1/2 | 1 | |
| Phase 3 | 3 |
| NCT ID | Title | Condition | Status | Updated |
|---|---|---|---|---|
| Phase 3 | ||||
| NCT03127267 | Efficacy and Safety of Masitinib Versus Placebo in the Treatment of ALS Patients | Amyotrophic Lateral Sclerosis | Recruiting | 2025-09-12 |
| NCT05564169 | Masitinib in Patients With Mild Alzheimer's Disease | Alzheimer Disease | Not Yet Recruiting | 2025-10-03 |
| NCT07174492 | Efficacy and Safety of Masitinib in Combination With SoC Versus Placebo in the Treatment… | Amyotrophic Lateral Sclerosis (ALS) | Not Yet Recruiting | 2025-10-03 |
| Phase 1/2 | ||||
| NCT05211570 | AB8939 in Patients With Relapsed/Refractory Acute Myeloid Leukemia | Acute Myeloid Leukemia Refractory | Recruiting | 2025-10-02 |
ALS (2) · Acute Myeloid Leukemia (AML) (1) · Alzheimer's Disease (1) · Leukemia (1) · Myelodysplastic Syndromes (MDS) (1)